EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 566 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology MOST POPULAR Teacher Is Glad She Asked for More Testing After Mammogram Failed... October 28, 2020 2023 ASCO Annual Meeting Research Round Up: Improving Symptom Monitoring and... September 21, 2023 20 Adorable Tiny Homes That Are Perfect For A Peaceful Weekend... July 9, 2019 Mirvetuximab Soravtansine-gynx Shows a Significant Benefit Over Chemotherapy in Women with... December 18, 2023 Load more HOT NEWS Safety of Antibiotics in the Context of First-Line Chemo-Immunotherapy for Advanced... Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy Five Questions With…Jessica, Katie, and Melanie
